The evidence supports prognostic risk estimation rather than a treatment effect; it may be inferred that validated risk predictions could help clinicians identify patients needing closer assessment or treatment-planning review, but the record does not show that nomogram-guided care improves survival or that radiotherapy itself is beneficial or harmful.

The reported case provides preliminary evidence that chondrocostal autografting can achieve short-term mandibular reconstruction after Ewing sarcoma resection in a growing child; it may offer a growth-compatible reconstructive option, but comparative durability, safety, oncologic compatibility, and effects on craniofacial growth remain untested.

The observed benign pathology and long recurrence-free follow-up support SANT as an indolent lesion in these resected cases; the proposal that biopsy-confirmed selected cases could be safely observed to avoid splenic surgery is an inference that was not tested and requires prospective validation.

The evidence supports age-dependent interpretation of hormonal profiles within PCOS/PMOS, particularly AMH; it does not test a therapy, and any use of these findings to guide diagnosis, monitoring, or treatment selection remains inferential.

Evidence: the WFRQ-K can measure family resilience strengths and needs in Korean families of children with chronic illness. Inference: if prospectively linked to targeted family-support interventions and patient or caregiver outcomes, it could help select supportive care and monitor benefit, but this study did not test an intervention or demonstrate improved clinical outcomes.

The reported evidence supports feasibility of national registry implementation, not a therapeutic intervention; indirectly, the resulting standardized data infrastructure could enable future identification of care gaps, outcome disparities, treatment patterns, and targets for quality improvement, but no improvement in treatment or survival is demonstrated here.

The study provides descriptive evidence that age-specific adrenal-mass profiles and management patterns differ; it may be inferred that pediatric-specific diagnostic and surgical triage pathways could improve treatment selection or avoid unnecessary intervention, but no therapeutic strategy or outcome benefit was tested.

The study provides no direct therapeutic evidence; it supports the inference that redirecting some research funding toward neglected priorities could generate interventions that improve treatment experience, supportive care, or outcomes, but whether such reallocation would produce effective therapies remains untested.

Evidence: survival improved across treatment eras, while metastatic disease identified a higher-risk group; inference: studying era-specific changes in multimodal care and intensifying or refining treatment strategies for metastatic disease could reveal opportunities to improve outcomes, but this record does not identify or test a specific therapeutic intervention.

Evidence: VR reconstruction was used clinically as an adjunct and received moderately favorable subjective usefulness ratings with high inter-rater agreement. Inference: better visualization could improve planning for anatomically complex pediatric urologic or oncologic surgery, but this record does not demonstrate improved operative, cancer, safety, cost, or patient outcomes.

The record supports further prospective study of linezolid–delamanid–clofazimine–cycloserine and linezolid–bedaquiline regimens for drug-resistant tuberculosis; any relevance to pediatric patients or children receiving cancer therapy is purely inferential and is not evaluated here.

The evidence supports closer adverse-event monitoring and toxicity-management strategies for children receiving methotrexate or NSAIDs for JIA; it only suggests, rather than establishes, that biologic DMARD-based treatment could reduce overall adverse-event risk because treatment selection and other confounding may explain the observational association.